Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC Guidelines for the management of acute coronary syndromes Developed by the task force on …
Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
F Gragnano, D Cao, L Pirondini, A Franzone… - Journal of the American …, 2023 - jacc.org
Background Aspirin is the only antiplatelet agent with a Class I recommendation for long- term prevention of cardiovascular events in patients with coronary artery disease (CAD) …
D Capodanno, U Baber, DL Bhatt, JP Collet… - Nature Reviews …, 2022 - nature.com
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …
J Kang, KW Park, H Lee, D Hwang, HM Yang… - Circulation, 2023 - Am Heart Assoc
Background: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal …
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - academic.oup.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Aims Patients at high bleeding risk (HBR) represent a prevalent subgroup among those undergoing percutaneous coronary intervention (PCI). Early aspirin discontinuation after a …